Saturday, October 25, 2014 Last update: Yesterday, 4:33 PM - Covering Large & Obscure Tech Companies Since 1996

With Molecular Tests, Clinical Labs Can Innovate Despite Daunting Reimbursement Crunch

Companies mentioned in this article: G2 Intelligence

KEENE, N.H. -- (BUSINESS WIRE) -- G2 Intelligence — a 30+ year leader in research, reporting, and analysis on the business of diagnostic medicine — today announced the final agenda for MDx NEXT, with dynamic sessions, case studies, and interactive panel discussions surrounding the theme: Molecular Diagnostics at the Crossroads: Innovation in the Face of a Reimbursement Crunch. G2’s annual event will be held at a new venue this year: the Royal Sonesta Harbor Court Baltimore, June 11-13, 2014.

“Molecular diagnostics. Genetic testing. Personalized medicine. Whatever you call it, this segment has long been a driver of growth — not only for clinical laboratories, but for diagnostic medicine as a whole,” says Stephanie Murg, G2’s Managing Director and conference program chair. “However, the struggle to innovate in the face of new and ongoing reimbursement challenges is an obstacle that raises a number of troubling questions. This year’s conference addresses these issues and helps molecular labs not only to grow in a difficult business environment but also to continue innovating.”

“As always, this year’s agenda is oriented toward helping a broad range of labs,” notes Kimberly Scott, G2’s Managing Editor and program co-chair. “In addition to reimbursement issues, we will also be tackling such timely topics as test ordering and results reporting, creating value around diagnosing infectious diseases and improving transplant outcomes, next-generation sequencing, and much more.”

Confirmed keynotes and general sessions include:

  • Keynote: Molecular Diagnostics at the Crossroads, with Matthew F. McManus, M.D., Ph.D., MBA, President, CEO, and Director, PrimeraDx
  • Keynote: The $1,000 Genome and Beyond, with Kevin Davies, Ph.D., Founding Editor, Nature Genetics and Bio-IT World; Author, The $1,000 Genome
  • Molecular Test Ordering and Results Reporting: How to Overcome the Challenges
  • Reimbursement Crunch: What It Means for Innovation and the Business of Molecular Diagnostics
  • Translating Test Results into Actionable Information at MolecularHealth
  • Molecular Diagnostics and the FDA: What Does the Future Hold?
  • Next-Generation Sequencing: The Challenges Ahead
  • After Code-Stacking: Critical Issues in Coding and Reimbursement
  • Paradigm Shift: Molecular-Based Testing for Personalized Patient Care
  • What Does the Myriad Case Really Mean for Molecular Diagnostics?
  • Genetic Counseling: What Labs Need to Know
  • And more!

Attendees can also enrich their experience with one or both pre-conference workshops on Wednesday, June 11:

  • Molecular Fundamentals: Starting Up and Running a Molecular Lab
  • Molecular Diagnostic Coding, Billing, and Payment: Strategies for Successful Reimbursement

To find out more, or to register for G2’s MDx NEXT conference, go to, or call 1-800-531-1026.

Group discounts are available for three or more people from the same organization. For group registrations, please call Jeff Watkins at 603-357-8229 to facilitate your registration, or email

About G2 Intelligence

Advancing the Business of Diagnostic Medicine

G2 Intelligence provides timely, accurate, and trusted analysis of industry and market trends, legal and regulatory developments, and technology and innovation that directly affect the operations, financial performance, and competitive position of diagnostic testing laboratories and related medical services providers.

G2 Intelligence has covered and reported on the diagnostic industry for over 30 years. Today, the company delivers topical and analytical periodicals, proprietary research studies, and custom advisory services, and through live and virtual events, facilitates industry meetings and information exchanges.

G2 Intelligence is a division of Kennedy Information, LLC, a leading provider of professional markets analysis. Kennedy’s parent company, Bloomberg BNA, a wholly owned subsidiary of Bloomberg, is a leading source of legal, regulatory, and business information for professionals. Its network of more than 2,500 reporters, correspondents, and leading practitioners delivers expert analysis, news, practice tools, and guidance — the information that matters most to professionals.

More information is available for you at

Copyright © Business Wire 2014

G2 Intelligence
Daniel Houder, +1-603-357-8101
Publisher, G2 Intelligence
President, Kennedy Information